menarini Menarini to buy Stemline for up to $677 million By www.pharmatimes.com Published On :: Tue, 05 May 2020 11:17:09 +0100 The move will establish Menarini's presence in the US biopharma market Full Article
menarini Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M By xconomy.com Published On :: Mon, 04 May 2020 20:45:58 +0000 Stemline Therapeutics, whose drug for a rare, aggressive type of acute leukemia was approved by the FDA about 18 months ago, has signed an acquisition deal with Italian biopharma Menarini Group. Stemline (NASDAQ: STML), a New York-based company, developed the first FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN. The drug, tagraxofusp (Elzonris) […] Full Article Europe blog main National blog main New York New York blog main New York top stories Acquisition Biotech blastic plasmacytoid dendritic cell neoplasm Blood Cancer BPDCN clinical trials Deal Elcin Barker Ergun Ivan Bergstein Life Sciences M&A Menarini Merger Oncology Precision Medicine Stemline Therapeutics transaction
menarini Menarini nabs hematologic malignancy drug along with buy of Stemline By www.thepharmaletter.com Published On :: Tue, 05 May 2020 12:32:00 +0100 Privately-held pharma and diagnostics firm Menarini Group has announced a definitive agreement to acquire… Full Article Biotechnology/Companies mergers and acquisitions/Elzonris/Hematology/Italy/Menarini Group/Oncology/One to Watch Companies/Rare diseases/Stemline Therapeutics/USA
menarini Menarini set to acquire Stemline for $677m By www.biopharma-reporter.com Published On :: Thu, 07 May 2020 14:53:00 +0100 Menarini adds Stemlineâs lead product, Elzonris, and its presence in the US with buyout deal. Full Article Markets & Regulations
